Skip to content

Study Details

Testing a Study Drug Upadacitinib for Adults and Adolescents with Abbvie Hidradenitis Suppurativa

(IRB#: IRB_00168703)

Abbvie Hidradenitis Suppurativa is a chronic (continues over time) painful skin condition that occurs in the places where the skin folds on the body. This study will test Upadacitinib to treat adults and adolescents with this disease. The study wants to see if the drug will help people with the disease and is safe. People in the study will be randomly chosen to be treated with Upadacitinib or a placebo. The placebo looks like the drug but does not have the medication. The drug and placebo are taken as a swallowed pill. During the study some participants may switch from taking Upadacitinib or the placebo. Being in the study requires multiple ways of participation such as writing in a journal at home and attending in person at a study clinic for about 2 years. Medical tests will be done during the study to track the health of participants.


  • All genders
  • Over 7 years old
  • Volunteers with special conditions
  •   In Person
  • Paid

Who can participate?

 Gender: All genders

  Age: Over 7 years old

  Volunteers: Volunteers with special conditions

   Location: In Person

Inclusion Criteria

  • Ages 12 years and older
  • Diagnosis of Hidradenitis Suppurativa at least 6 months prior to participation
  • Hidradenitis Suppurativa must be present on at least 2 parts of the body
  • Willing and able to fully participate in all required study activities
  • Use specific birth control approved by the study

Exclusion Criteria

  • History of active skin disease other than Hidradenitis Suppurativa
  • Treated with another study drug 30 days before receiving first dose of the study drug
  • Receive a live vaccine, such as the flu vaccine, with similar parts of the study drug 28 days prior to the first dose of the study drug
  • History of drug or alcohol abuse 6 months prior to participation
  • Pregnant or breastfeeding

Will I be paid for my time?


For more information contact:

Anjelica Ashworth


IRB#: IRB_00168703

PI: Jamie Rhoads


Approval Date: 2023-12-20 07:00:00

Specialties: Dermatology

Last Updated: 6/8/23